Hedge funds loved Micron ahead of its run to $1 trillion. Here are their other favorite stocks
The Goldman Sachs VIP basket has outperformed the S&P 500 this year, through last Friday.
Uncategorized
Insurance companies are buying back their own stock in hordes. Maybe they shouldn’t
Insurers are revisiting an old playbook from past down cycles, repurchasing stock to prop up earnings per share by shrinking the share count.
Insurance companies are buying back their own stock in hordes. Maybe they shouldn’t Read More »
This airline stock could be a big winner as oil prices stabilize. How to trade it
Tony Zhang breaks down how he’s trading this airline name.
This airline stock could be a big winner as oil prices stabilize. How to trade it Read More »
FedEx is a buy as freight business spinoff approaches, JPMorgan says
The shipping company’s stock is looking more attractive as it prepares to spin out its freight business on June 1, per JPMorgan.
FedEx is a buy as freight business spinoff approaches, JPMorgan says Read More »
Chip stocks continue to surge. Here’s how to buy into the trend for less
Mike Khouw happens to like one surging chip stock in particular: Marvell Technology.
Chip stocks continue to surge. Here’s how to buy into the trend for less Read More »
Credit ‘FEMO’ for driving the market higher despite Iran and other worries. Here’s what it means
Ed Yardeni argues there’s a new driver for stocks.
The Avis ‘circus’ messed with the transports sector this year. Josh Brown finds the real Best Stocks in the space
Josh Brown and Sean Russo take a look at some of the transportation names in their Best Stocks list.
A defense stock down big lately is primed for a turnaround. How to play a comeback with less risk
Northrop Grumman has suffered an eye-popping 30% collapse in under two months.
Goldman says this biotech stock will be a winner thanks to a one-of-a-kind treatment
Hemab Therapeutics is likely to gain ground as its treatment for a pair of rare bleeding disorders shows signs of efficacy, per Goldman Sachs.
Goldman says this biotech stock will be a winner thanks to a one-of-a-kind treatment Read More »